



STEM CELL PROCESSING CENTER

CONTACT INFO

📞 001 786 238 2170
✉ info@stemcellsgroup.com
🌐 www.adimarket.net



ADIMARKET

A DIVISION OF GLOBAL STEM
CELLS GROUP

info@stemcellsgroup.com



ADIMARKET

A DIVISION OF GLOBAL STEM
CELLS GROUP

www.adimarket.net



ADIMARKET

A DIVISION OF GLOBAL STEM
CELLS GROUP

BUSINESS PROPOSAL / INVESTMENT OPPORTUNITY

Adimarket, LLC
14750 NW 77th CT
Miami Lakes, FL 33016
United States

CONTACT INFO

☎ 001 786 238 2170
✉ info@stemcellsgroup.com
🌐 www.adimarket.net



EXECUTIVE SUMMARY

BUSINESS OVERVIEW

Global Stem Cells Group is a collection of leading edge companies in the explosively growing stem cell therapy market. The Company is a leader in stem cell research, patient applications, and training through its state-of-the-art global network of companies. Global Stem Cells Group's mission is to enable physicians to make the benefits of stem cell medicine a reality for patients around the world.

The Company's subsidiary businesses service various aspects of Regenerative Medicine including:

- Sales of technology, supplies and equipment.
- Proprietary Protocols for Stem Cell Processing and Clinical Applications
- Certified Training courses for physicians.
- Turn Key solutions for Stem Cell Processing Center installation and management
- Franchise Network of Regenerative Medicine Practitioners

As the parent company, Global Stem Cells Group specializes in leading-edge stem cell research, patient application and physician training. Members of its distinguished scientific advisory board are on the cutting edge of regenerative medicine. The Company's subsidiaries all provide world-class leadership in the markets they serve:

Stem Cell Training (Educational Arm of ISSCA International Society for Stem Cell Application)

Comprehensive Regenerative Medicine Training Institute with products ranging from Online resources to fully accredited postgraduate studies in Cell Therapy and Tissue Engineering (www.stemcelltraining.net) (www.stemcellsacademy.com) (www.stemcellscourse.com)

Adimarket

Outfitting laboratories of all sizes, from an in office minimal manipulation set up to a complete culture expansion and Cryopreservation High Manipulation Lab (www.adimarket.net) (www.stemcellslab.net)

Stem Cell Center Network

A worldwide membership network of leading physicians who practice Regenerative Medicine under the company's banner (www.stemcellcenter.net)

ISSCA

A non-profit organization that promotes guidance on stem cell research and patient applications www.stemcellglobal.org

EXECUTIVE SUMMARY

In its 8-year existence, Global Stem Cells Group has been able to establish a global presence. The Company provides training in 35 cities around the world. It conducts Medical Conferences and educational symposiums and large medical gatherings with the purpose of training physicians in regenerative medicine techniques. (www.stemcellconference.org) It is associated with more than 25 clinics that are all certified to meet international standards for regenerative medicine and medical tourism.

As a recognized leader in the exploding field of regenerative medicine, Global Stem Cells Group is focused on delivering the latest advances, the most up to date training, the knowledge of experts and the broadest real-world experience in regenerative medicine to physicians around the world.

Global Stem Cells Group has a network of physicians in more than 25 countries practicing Regenerative Medicine under our Protocols and our brand name . These countries include India, Spain, Korea, Costa Rica, Colombia, Morocco, Paraguay, Argentina, Dominican Republic, Chile, Perú, USA, México, Panamá, Bolivia, Ecuador and Iraq. The Company also has deep clinical relationships with hospitals and private clinics in Cozumel and Cancun.

The Company has the largest membership network of Regenerative Medicine Clinics in the world (the Stem Cell Center Network) whose mission is to make the promise of stem cell medicine become a reality for patients around the world. Stem Cell Center Inc is a licensing company that licenses its name and IP to doctors around the globe. The Stem Cell Center program consists of a rapidly expanding network of physicians who are assigned an exclusive territory within their country and / or specialty. Each physician is trained by the Company's competent staff, secures all necessary medical equipment and supplies to perform stem cell treatments, contracts to perform stem cell treatments, contracts with the Company to market, recruit and forward patients to their practice

MARKET OPPORTUNITY

Although the use of stem cells in medical research and treatment has been controversial, it remains extremely promising. While the use of embryonic stem cells has been severely restricted, there are numerous legal autologous stem cell transplant programs operating in the US today. More than 190,000 people were treated with stem cell therapy in 2016 alone.

A report by Robin Young and the New York Stem Cell Summit '12 indicates that stem cell therapies are set for explosive growth both in the US and internationally. Products for cardiovascular disease, diabetes, nerve repair and other medical procedures will soon achieve widespread availability

EXECUTIVE SUMMARY

Global Stem Cells Group has a great opportunity. As autologous stem cell therapy demand explodes in the US and globally, the Company's unique approach utilizing several different business entities to address each of the market needs will prove very beneficial. Global Stem Cells Group can become a recognized leader in the massive stem cell therapy market.

STRATEGIC ADVANTAGE

Stem Cell therapies are in their infancy and will continue to grow in popularity not only among the general public but also through the medical community. Patient searches for stem cell therapies are growing every year. Furthermore, physicians are eager to learn new and simple ways to incorporate cellular medicine in their practices. Additionally, patients that are suffering from terrible chronic debilitating diseases know that the current healthcare system will not help them but will only alleviate symptoms.

The current management team has been successfully working in the cellular and aesthetic field for over eight years. The management team has experience in growing regenerative medical practices from in-office startup to fully accredited complex laboratories. The Company in conjunction with its consulting physicians and scientist has set up and equipped Regenerative Medicine practices and Laboratories in over four(4) continents. The Company has trained over 1,500 doctors from across the globe in Regenerative Medicine Techniques.

The Company is seeking investment to build a highly advanced. Stem Cell Laboratory in Cancun Mexico and San Jose Costa Rica which will represent a tremendous competitive advantage and differentiator since it will allow the Company to have the ability to perform highly advanced stem cell procedures in the region of the world where the largest populations of patients are located. Global Stem Cells Group collection of companies represents a self-reinforcing vertical enterprise.

EXECUTIVE SUMMARY

PROJECTIONS

The three year projections are based on the assumption that at least \$1 million of investment is obtained.

Cash Flow Positive
each month

Positive net income
each year

Operating income
\$7.6M in Year 3

Net income \$4.6M
in Year 3

		Year 1	Year 2	Year 3
Income	Product Sales	1,356,000.00	2,576,400.00	4,379,880.00
	Patient Treatment	3,600,000.00	6,120,000.00	10,404,000.00
	Physicians Training	422,568.00	718,365.60	1,221,221.52
Total Income		5,378,568.00	9,414,765.60	16,005,101.52
Cost of Goods Sold	Cost of Goods Sold	631,988.00	947,982.00	1,421,973.00
Total COGS		631,988.00	947,982.00	1,421,973.00
	Gross Profit	4,746,580.00	8,466,783.60	14,583,128.52
	Business Licenses and Permits	25,000.00	25,000.00	25,000.00
	Comissions	853,000.00	1,706,000.00	3,412,000.00
	Marketing and Advertising	422,000.00	844,000.00	1,688,000.00
	Meals and Entertainment	3,856.50	77,300.00	112,000.00
	Payroll	154,000.00	308,000.00	616,000.00
	Medical Supplies Misc	54,000.00	108,000.00	186,000.00
	Professional Fees	374,000.00	748,000.00	1,496,000.00
	Rent Expense	78,000.00	125,000.00	125,000.00
	Repairs and Maintenance	50,000.00	50,000.00	75,000.00
	Misc	56,000.00	112,000.00	224,000.00
	Travel Expense	46,232.00	92,464.00	184,928.52
		2,150,882.00	4,195,764.00	8,143,928.52
	Net Income	2,595,698.00	4,271,019.60	6,439,200.52

OBJECTIVES

Treat at least 180 patients in Year 1 and 225 in Year 2

EXIT

Global Stem Cells Group's investors will share in the increased valuation of the Company as revenues grow, the balance sheet becomes stronger, and the Company attains a market leadership position. In conjunction with its investors, Global Stem Cells Group management will pursue viable exit strategies once the Company reaches a critical mass. The Company's management believes that it can attain an attractive outcome for all shareholders.

STRATEGY

GO TO MARKET

Global Stem Cells Group's go to market strategy has two key components.

- 1) Target both patients and physicians
- 2) Provide a state of the art facility, where patients can obtain the stem cell therapy they seek

By creating a collection of companies that support and complement one another, the Company can direct its marketing and sales efforts at identifiable and easily reachable targets and avoid having its efforts spread too thin. Furthermore, with its broad reach into both: the patient and the physician communities, Global Stem Cells Group will quickly become a recognized leader in stem cell therapy.

Global Stem Cells Group's Stem Cell Processing Center will be able to provide a level of service and improved medical outcomes that other stem cell therapy companies will not. Patients will certainly be attracted to a company like Global Stem Cells Group, that can offer the most advanced medical care and unmatched medical outcomes. The Company can now expand in the US. Due to the processing center being located in Mexico all reintroduction of cultivated stem cells must be done outside of the United States. That is why the Company's International Stem Cell processing center becomes so important.

The Company will aggressively pursue patients and physicians and build a large community of people working with stem cell therapies. The Company will utilize testimonials and true stories of successful treatments in a strong PR campaign to educate the public about the benefits of stem cell therapy

COMPETITIVE EDGE

There is no other stem cell therapy company that can offer the breadth of education, services and products to both patients and physicians. Hence, the Company can assume a market leadership position in this rapidly growing field of advanced medicine.

Finally, the Company's proposed new Stem Cell Processing Center provides it with a strong competitive advantage. Instead of being limited by the uncertain regulatory environment in the US, Global Stem Cells Group will be able to offer patients enhanced treatment options not available domestically

MARKET ANALYSIS

MARKET OVERVIEW

Physicians are just now receiving a set of tools to treat diseases, injuries and aging that can only be called revolutionary. These tools are autologous (derived from the patients themselves) stem cells that are amplified in culture and then infused back into the patient according to a precise protocol.

One common therapeutic use of stem cells by US physicians is to harvest them from one part of the body and then re-implant them at the site of an injury—where they are most needed but are in short supply. This can be an effective way to stimulate healing at sites of injury. But the one problem is that the quantity of stem cells is only as good as the patient's supply. To counteract this limitation, an effective strategy is to grow the patient's stem cells in a culture media.

However, the above approach introduces the danger of these new therapies facing regulatory scrutiny by the FDA. The FDA is trying to establish its jurisdiction by saying that, any culturing of stem cells (regardless of the scope or purpose) it's a prescription drug. However, physicians and organizations are pushing back by arguing that stem cell therapy is the practice of medicine and the FDA isn't chartered to do that. They liken it to infertility clinics where physicians must grow a woman's fertilized oocytes. So organizations such as The American Stem Cell Therapy Association (ASCTA) are being formed to establish guidelines and standards.

As more studies about the benefits of autologous stem cells become available, the use of the technology will explode. Clinical outcome studies are already showing the benefits of bone marrow stem cell therapy for heart attack patients and other conditions. As these success stories proliferate, more people will demand stem cell therapy from their physicians, and the market will grow exponentially.

MARKET SIZE




According to Market Research, the Global Stem Cells Market was valued at USD 5.88 Billion in 2018 and is expected to witness a growth of 10.32% from 2019-2026 and reach USD 12.96 Billion by 2026.

MARKET ANALYSIS

MARKET SEGMENTS

The stem cell therapy market is forecasted to be driven by several segments. The diagram to the right shows what percentage of the market each segment is expected to capture



GLOBAL STEM CELLS GROUP AUDIENCES

- * Physicians
- * Patients
- * Hospitals
- * Researchers

CUSTOMER CHARACTERISTICS

The Company's market is global. It seeks to reach physicians and patients from around the world. However, a main focus is US licensed physicians since patients searching the internet for treatment will always feel more comfortable with trained doctors versus foreign doctors.

Global Stem Cells Group has established a goal of building a State of the Art Stem Cell Processing Center in Cancun Mexico

CUSTOMER PROFILE

The patients using the Company's services would include patients looking to treat Chronic conditions including erectile dysfunction, hair loss, diabetes, COPD, sports injuries, facial and body rejuvenation, repair damaged joints and to repair, rejuvenate and fill the skin. Patients are expected to come from around the world looking for advanced treatments for the conditions just mentioned.

Physicians and patients utilizing the Company's services and products will also be from locations around the world.

MARKET ANALYSIS


TARGET MARKET AND SIZE

Global Stem Cells Group has identified a clear and substantial target market. The Company will target physicians as referral sources worldwide.

The Company will also target patients worldwide and especially the US

US Onl	Sample Patient Markets	
US Onl	US Cosmetic Surgery Market	
	3.3 million seniors 5 years and older (1)	3.3 million
	Market size in 2017 (2)	\$3.2 billion
	Men with erectile dysfunction in US (3)	30 million
	Hair loss market size (4)	\$543 million
	Skin care market in US in 2013 (5)	\$4.97 billion
	Small joint, small bone and extremity devices in 2017 (6)	\$2.4 billion

Physicians per 10,000 population



Source <http://www.globalhealthfacts.org/data/topic/map.aspx?ind=74>

STEM CELL THERAPY MARKET

The market is expected to experience exponential growth in stem cell procedures. The demand of patients to receive the benefits of stem cell procedures will increase correspondingly.

FINANCIAL PROJECTIONS

REVENUE ASSUMPTIONS

The following are the revenue assumptions.



Revenue Assumptions			
	Year 1	Year 2	Year 3
Patient Fees Chronic Diseases	\$1,837,500	\$3,412,500	\$4,305,000
Aesthetic Conditions	\$570,000	\$759,000	\$1,170,000
Auto Immune Diseases	\$620,000	\$845,000	\$1,070,000
Referrals from network doctors	\$440,000	\$600,000	\$800,000
Other Regenerative Med	\$1,860,000	\$3,920,000	\$6,654,000
Referral Income	\$380,700	\$445,050	\$508,950

FINANCIAL PROJECTIONS

PROJECTED PROFIT AND LOSS



Global Stem Cells Group's Stem Cell Processing Center revenues are projected to grow significantly. Monthly revenue will peak at \$685,000. Revenues for Year 1 will exceed \$5.7 million, and this will yield an operating profit of \$2.2 million.

Revenues will continue to grow annually and reach \$14.5 million in Year 3. Operating profit will exceed \$7.6 million, and net income will exceed 4.6 million.



BALANCE SHEET AND CASH FLOW

Global Stem Cells Group's balance sheet remains strong, and cash flow is sufficient to support its operations, as illustrated in the following graphs.



INVESTOR RETURN

INVESTOR RETURN

Global Stem Cells Group is currently looking for an equity investment of \$1 million. These funds are sufficient to allow the Company to build and successfully operate the Stem cell Processing Center, and achieve its business goals.

Management is resolute in its plan to promote and market Global Stem Cells Group's Stem Cell Processing Center to a wide variety of physicians and patients on the largest scale possible. The management team is confident that the Company is poised to realize great success.

The value of Global Stem Cells Group's shares will increase as the Company achieves its goals. The investor will be secure in knowing that the Company's valuation is increasing as revenues grow, the balance sheet becomes stronger, and the Company attains a strong market position.

MINI
CO₂ INCUBATOR

MEDIUM
CO₂ INCUBATOR

ADIMARKET

A DIVISION OF GLOBAL STEM
CELLS GROUP

info@stemcellsgroup.com

STEM CELL PROCESSING CENTER COMPLETE SOLUTION FOR A REGENERATIVE MEDICINE LAB

Our stem cell laboratory solution represents a tremendous competitive advantage and differentiator allowing our clients the ability to perform highly advanced stem cell procedures

What is it?

It is a complete solution for tissue processing, isolation, culturing and cryopreservation of stem cells following the strictest scientific protocols to ensure:

- Better clinical interpretation
- Better results
- Compliance with safety regulations and international standards.

Stem Cell Processing Center offers your practice the ability to become a high complexity in-office laboratory in a relatively small space. You give us an area. We will design a validated biological clean room with state-of-the-art laboratory equipment, along with the specialized training to implement high-level laboratory processes.

Our Turnkey Cell Processing Center Projects Team specializes in delivering highly customized laboratory projects providing our clients with a cohesive and cost-efficient solution.

- Analysis of the requirements of the laboratory
- Procurement of equipment and other deliverables
- Furniture, laminar flow hoods, laboratory tables, etc
- Equipment and instruments within the laboratory
- Delivery to site
- Installation
- End user Training


Adimarket, LLC
14750 NW 77th CT
Miami Lakes, FL 33016
United States

CONTACT INFO

001 786 238 2170
info@stemcellsgroup.com
www.adimarket.net



WHAT WE DO



ANALYZING LABORATORY REQUIREMENTS AND PROCURING EQUIPMENT.

Our work is a comprehensive turnkey solution for the set-up and operation of a laboratory for the culture of human pluripotent Stem Cells. The process of establishing a STEM CELL PROCESSING CENTER can be divided into two equally important parts. One is completely administrative and includes developing protocols, seeking approval, and establishing reporting processes and documentation. The other part of establishing a STEM CELL laboratory involves the physical plant and includes design, equipment and personnel.

PLANNING OF LABORATORY OPERATIONS AND PHYSICAL LAYOUT DESIGN.

To operate a successful stem cell processing center, we will provide and install the necessary equipment required for culture and characterization of hPSCs. We are proponents of a modular design option, both regarding laboratory benches and equipment, allowing the space to be expanded as needed by adding additional tissue culture modules and personnel to manage the workload

DELIVERY & INSTALLATION

Delivery and installation is the pivot point of any project. We guarantee proper planning, coordination and communication. Our project management and installation teams take great pride in the finished product and have extensive experience with laboratory projects and international shipping.

END-USER TRAINING

During our comprehensive training program, a group of experienced academicians and scientist, will teach our proprietary protocols and cover the general principles and practice of stem cell biology and evidence-based treatments for laboratory staff to optimize their performance.

OUR PROCESS

Initial Assessment

We will take the necessary time to understand your individual needs and provide a complete solution to your laboratory.

Budgeting & Estimating

Our professional estimating team provides overall project pricing and contract documentation. We work with our clients to determine the right solution to meet their project goals and budget. We invite you to learn on the know-how of our Estimating staff to provide you with a detailed and accurate estimate today!

Project coordination

Our company will begin a project by developing a detailed Timeline & Delivery schedule coordinating: procurement, submittals, fabrication, training, shipping and installation times.



ADIMARKET

A DIVISION OF **GLOBAL STEM
CELLS GROUP**

☎ 001 786 238 2170

✉ info@stemcellsgroup.com

🌐 www.adimarket.net

CONTENTS

We provide the ultimate solution for your needs, and all we require is for you to provide the location. This will allow us to develop a perfect biological clean room with the highest level of quality in products and laboratory equipment for your needs.

Our goal is to provide the highest level of service, along with the proper training. This will ensure that you can make the best possible use of your laboratory.

► FACILITY & EQUIPMENT ----- 20

► CORE TECHNOLOGY ----- 43

► PROJECT PLAN ----- 53

FACILITY & EQUIPMENT

We provide the ultimate solution for your needs and all we require is for you to provide the location. This is going to allow us to proceed with a design that will include a perfect biological clean room with the highest level of quality in products and laboratory equipment for your needs.

Our goal is to provide the ultimate service and we will also give you proper training in order to ensure that you are able to make the best possible use of your laboratory.



STEM CELL PROCESSING CENTER (SPC)

CLEAN ROOM

- Construction
- Pre-operation



1

2



EQUIPMENT

Installation
Validation
Training

TECHNOLOGY

- Cell processing
- Quality control
- Treatment



3

BIO-CLEAN ROOM FEATURES



WHY BIOCLEAR ROOM?

- Aseptic Environment, No contamination
- Air conditioned system
- Optimal Environmental monitoring for cell culture.

BIO CLEAN ROOM

BIOCLEAN ROOM MUST HAVE:

CONDITION OF BCR

- 1 Height must be higher than 4.5m
- 2 Emergency electricity
- 3 Antistatic facility
- 4 Differential pressure
- 5 Differential cleanliness
- 6 Interlock system

Cleanliness





Air pressure flow




Person, waste, material flow



Inter-lock system



STEM CELL PROCESSING CENTER LAYOUT:




1 Aseptic cell culturing area

2 Quality control area

3 Preparation area

4 Utility area




5 Storage



2. QUALITY CONTROL AREA

Good laboratory practice requires testing normal and abnormal controls for each process at least daily to monitor the analytical process. If the test is stable for less than 24 hours or some change has occurred which could potentially affect the test stability, controls should be assayed more frequently.


- Endotoxin Test
- Mycoplasma Test
- Aseptic Test
- Stem Cell Quality Test




BIO CLEAN ROOM

3. PREPARATION AREA

- Cell Storage -
- Reagent Storage -
- Reagent Preparation -
- LN2 Supply -



To operate a successful stem cell processing center, we need to install the basic equipment required for culture and characterization of hPSCs. Some Clients may require specialized culture equipment, such as incubators that allow culture in low oxygen tension, or characterization and analysis equipment. Here we list some the equipment required to establish a standard hPSC culture laboratory.



EQUIPMENT

CLEAN BENCH



CO₂ INCUBATOR



DEEP FREEZER



CENTRIFUGE



SHAKING INCUBATOR



WATER BATH



DRY OVEN



LN₂ STORAGE TANK



EQUIPMENT

DRY HEAT STERILIZER



AUTOCLAVE



SUCTION MASTER



INVERTED MICROSCOPE



MICROSCOPE CAMERA



LABELING EQUIPMENT



ULTRASONIC CLEANER



BALANCE



EQUIPMENT

LN₂ SUPPLY TANK



**FACS
(FLOW CYTOMETRY)**



ELISA READER



**STERILITY
TEST PUMP**



LUMINOMETER



PH METER



BOD INCUBATOR



REFRIGERATOR



EQUIPMENT

THERMAL BLOCK



HOT PLATE & STIRRER



VORTEX MIXER



AUTOClave



MINI- CENTRIFUGE



PARTICLE COUNTER



AIR SAMPLER



CO₂ ANALYZER



WATER PURIFICATION SYSTEM




WATER PURIFICATION SYSTEM



RESEARCH EQUIPMENT

CELL IMAGING SYSTEM



FLUOROMETER



BIO PROCESS ANALYZER



PCR



EC DECLARATION OF CONFORMITY

CE

On this day the following signatories certify:

EC Representative
WITTEN, Inc. 40-01 30th
Staten Island, NY 10314

I hereby, on the sole authority of the signatory of this Declaration, **WITTEN, Inc.** (hereinafter "WITTEN"), certify that the product, **WITTEN 1000**, is in conformity with the applicable requirements of the **EMC Directive (89/332/EEC)** and **CE Marking** according to the EMC Directive and the EMC Directive Annexes, and that the product is in conformity with the EMC Directive and the EMC Directive Annexes.

EMC 1000 **EMC 1000** **EMC 1000**
EMC 1000 **EMC 1000** **EMC 1000**
EMC 1000 **EMC 1000** **EMC 1000**
EMC 1000 **EMC 1000** **EMC 1000**
EMC 1000 **EMC 1000** **EMC 1000**

The Declaration is the responsibility of the signatory. WITTEN

J. WITTEN, Inc.
100-01, 30th Ave., 10th Fl.,
Staten Island, New York, 10314-3000, U.S.A.

This Declaration is valid and complete and has been signed by: **WITTEN, Inc.** **EMC 1000**

Manufacturer/Importer

Signature: _____
Name: _____
Title: _____
Company: _____
Address: _____
City: _____
State: _____
Country: _____
Telephone: _____
Fax: _____
E-mail: _____

This Declaration is valid and complete and has been signed by: **WITTEN, Inc.** **EMC 1000**

MANUFACTURE PATENT & CERTIFICATION

[illegible]

MONITORING SYSTEM



GLOBAL STEM CELLS GROUP

COMPLETED PROJECT

When building out new laboratory space, our design team usually includes an architect, a contractor, a builder, an electrician, a mechanic, a plumber, and a laboratory director or manager.

The dynamic nature of biomedical research and the cost of laboratory construction have resulted in the prevalent use of a modular design that allows reconfiguration of the laboratory as needed while keeping construction costs to a minimum.



SOUTH KOREA
SEOUL UNIVERSITY



info@stemcellsgroup.com

STEM CELL TREATMENT CENTER

COMPLETED PROJECT

SOUTH KOREA 

BELITA PLASTIC SURGERY CLINIC



STEM CELL COSMETIC CENTER

GLOBAL STEM CELLS GROUP

COMPLETED PROJECT



SOUTH KOREA

GRIM PLASTIC SURGERY CLINIC



STEM CELL TURN KEY SOLUTION

info@stemcellsgroup.com

IN PROGRESS

JAPAN
KYOTO



CONSTRUCT CELL THERAPY CENTER

GLOBAL STEM CELLS GROUP



CHINA
BEIJING



CONSTRUCT CELL THERAPY CENTER

info@stemcellsgroup.com



info@stemcellsgroup.com




☎ 001 786 238 2170

✉ info@stemcellsgroup.com

🌐 www.adimarket.net

CORE TECHNOLOGY



Our Company has been certified by Independent and international reviewers, we have achieved the highest possible standard and quality of services.

PATENT III STEM CELL CULTURE MEDIA




GLOBAL STEM CELLS GROUP

Growing cells in the laboratory are known as cell culture. Cultured Autologous Human stem cells are generated by transferring cells into a plastic laboratory culture dish that contains a nutrient broth known as culture medium. The cells divide and spread over the surface of the dish.

Those Cells will divide and multiply enough to crowd the dish; they are removed gently and plated into several fresh culture dishes. The process of re-plating or subculturing the cells is repeated many times and for many months.


At any stage in the process, batches of cells can be frozen and shipped to other laboratories or Clinics for further culture or treatment to patients

Stem Cell Mass production



Stem Cell Cryopreservation

Viability and recovery rate after cell cryopreservation



Quality Control

Classification		KOREA (KPC)	U.S (USP)	Europe (EP)	N-BIOTEK
Endo- toxin	Sample Endotoxin	≤ 5.0 EU/KG/hour	≤ 0.5 EU/ml	≤ 5.0 EU/KG/hour	≤ 0.3 EU/ml
	Linearity	CORR ≥ 0.98	CORR ≥ 0.98	CORR ≥ 0.98	CORR ≥ 0.98
	Reproducibility	CV < 10 %	CV < 10 %	CV < 10 %	CV < 10 %
	Inhibition /Enhancement rate	50~200 %	50~200 %	50~200 %	50~200 %
Mycoplasma (Analyzing time)		More than 14 days	More than 14 days	More than 14 days	Less than 30 minutes. Cross contamination prevention
Aseptic test		0 CFU	0 CFU	0 CFU	0 CFU
Total Organic Carbon(TOC) test		<0.5 mg/ml	<0.5 mg/ml	<0.5 mg/ml	<0.5 mg/ml

Virus is detected and prevented through the pre-blood test
 # Global applies stricter regulation than U.S and European GMP guideline

GLOBAL STEM CELLS GROUP

Good Laboratory Practice(GLP) Nonclinical trial result

- 1 No unscheduled deaths
- 2 No change of weight, amount of drink
- 3 No histopathologic problem

FINAL REPORT

Single-Dose Intravenous Toxicity Study of Human Adipose Stem Cell in C.B-17 SCID Mice

Study Number: 13-MA-043

Sponsor: N-BIOTEK

Nonclinical Research Institute, ChemOn Inc.



Nonclinical Research Institute, ChemOn Inc.
210, Namgyeong-ro, Yangju-siyeon, Chosun-gu, Yangju-si, Gyeonggi-do,
440-820 Republic of Korea

ChemOn Study No. 13-MA-043

Results

Mortality (Table 1; Appendix 1-1)

There were no unscheduled deaths in the vehicle control and all treatment groups.

Clinical signs (Table 2; Appendix 1-1)

There were no toxic signs recorded in the vehicle control and all treatment groups.

Body weight (Table 3; Appendix 1-2)

There were no statistically significant differences in treatment groups when compared with that of the vehicle control groups.

Necropsy findings (Table 4; Appendix 1-3)

There were no gross findings recorded at any dose level. Therefore, histopathologic examination was omitted after consulting with the sponsor.

**APPROXIMATE
COST**

Cell Process & Banking

Small Unit space: 100m ²	
FACILITY	<ul style="list-style-type: none">• CPC : Bio Clean room + Q/C area + Storage room
EQUIPMENT (CPC)	<ul style="list-style-type: none">• Cell Banking Equipment• Quality Control Equipment• Environmental Check Equipment• Monitoring system

Size and cost can be customized according to partner's demand and situation


Example for Cell Culturing

Larger Capacity space: 500m ²	
FACILITY	<ul style="list-style-type: none">● CPC : Bio Clean room + Q/C area + Storage room + Others● Treatment Part : Operation room, Treatment room, Beauty room and Interior design
EQUIPMENT (CPC)	<ul style="list-style-type: none">● Cell Culture Equipment● Quality Control Equipment● Environmental Check Equipment● Monitoring system
TECHNOLOGY	<ul style="list-style-type: none">● Stem Cell Processing Technology● Quality Control Technology● Facility Management

Size and cost can be customized according to partner's demand and situation

SCOPE OF OPERATIONS

STEM CELL CENTER





ADIMARKET

A DIVISION OF GLOBAL STEM
CELLS GROUP

info@stemcellsgroup.com



ADIMARKET

A DIVISION OF **GLOBAL STEM CELLS GROUP**

001 786 238 2170 

info@stemcellsgroup.com 

www.adimarket.net 


PROJECT PLAN



PROJECT PLAN

STEM CELL TURN KEY SOLUTION

We will design the complete laboratory: premises, laboratory furniture , analytical systems as well as the complete utilities supply respectively disposal.



■
BIO CLEAN ROOM
CONSTRUCTION

■
LIFE SCIENCE
EQUIPMENT

■
STANNDARDIZED
TECHNOLOGY
TRANSFER

PARTNER



SCOPE OF ACTIVITIES

- Compilation of tender documents for the construction of a new laboratory
- General planning, Feasibility studies and estimation of costs
- Project management and supervision during the implementation
- Execution: Delivery, installation and training

Afterwards the implementation of the project proceeds with the object surveillance as well as the supervision of the object and the documentation in capacity of the project management.

Classification		Month	1	2	3	4	5	6
Facility	Facility Design	0.7	→					
	Clean room	3.3	→	→	→	→		
	Validation, pre-test	1				→		
HHRR	Researchers Lab Personnel	2		→	→			
Equipment	Manufacturing	3	→	→	→			
	Installation	1				→		
	Validation, pilot test	1				→		
Laboratory	Consumable order and delivery	3		→	→	→		
Technology	Clean CPC, Technology Training at Local Facility	0.5					→	
	Initial Cell Processing	2					→	→

Estimated Time (6 months).



info@stemcellsgroup.com



ADIMARKET

A DIVISION OF GLOBAL STEM
CELLS GROUP

info@stemcellsgroup.com



ADIMARKET

A DIVISION OF GLOBAL STEM
CELLS GROUP

Adimarket, LLC
14750 NW 77th CT
Miami Lakes, FL 33016
United States

CONTACT INFO

001 786 238 2170
info@stemcellsgroup.com
www.adimarket.net